A computational model of drug dissolution in the human stomach is developed to investigate the interaction between gastric flow and orally administrated drug in the form of a solid tablet. The stomach model is derived from the anatomical imaging data and the motion and dissolution of the drug in the stomach are modeled via fluid-structure interaction combined with mass transport simulations. The effects of gastric motility and the associated fluid dynamics on the dissolution characteristics are investigated. Two different pill densities are considered to study the effects of the gastric flow as well as the gravitational force on the motion of the pill. The average mass transfer coefficient and the spatial distributions of the dissolved drug concentration are analyzed in detail. The results show that the retropulsive jet and recirculating flow in the antrum generated by the antral contraction wave play an important role in the motion of the pill as well as the transport and mixing of the dissolved drug concentration. It is also found that the gastric flow can increase the dissolution mass flux, especially when there is substantial relative motion between the gastric flow and the pill.
more »
« less
Measuring dissolution profiles of single controlled-release drug pellets
Abstract Many solid-dose oral drug products are engineered to release their active ingredients into the body at a certain rate. Techniques for measuring the dissolution or degradation of a drug product in vitro play a crucial role in predicting how a drug product will perform in vivo. However, existing techniques are often labor-intensive, time-consuming, irreproducible, require specialized analytical equipment, and provide only “snapshots” of drug dissolution every few minutes. These limitations make it difficult for pharmaceutical companies to obtain full dissolution profiles for drug products in a variety of different conditions, as recommended by the US Food and Drug Administration. Additionally, for drug dosage forms containing multiple controlled-release pellets, particles, beads, granules, etc. in a single capsule or tablet, measurements of the dissolution of the entire multi-particle capsule or tablet are incapable of detecting pellet-to-pellet variations in controlled release behavior. In this work, we demonstrate a simple and fully-automated technique for obtaining dissolution profiles from single controlled-release pellets. We accomplished this by inverting the drug dissolution problem: instead of measuring the increase in the concentration of drug compounds in the solution during dissolution (as is commonly done), we monitor the decrease in the buoyant mass of the solid controlled-release pellet as it dissolves. We weigh single controlled-release pellets in fluid using a vibrating tube sensor, a piece of glass tubing bent into a tuning-fork shape and filled with any desired fluid. An electronic circuit keeps the glass tube vibrating at its resonance frequency, which is inversely proportional to the mass of the tube and its contents. When a pellet flows through the tube, the resonance frequency briefly changes by an amount that is inversely proportional to the buoyant mass of the pellet. By passing the pellet back-and-forth through the vibrating tube sensor, we can monitor its mass as it degrades or dissolves, with high temporal resolution (measurements every few seconds) and mass resolution (700 nanogram resolution). As a proof-of-concept, we used this technique to measure the single-pellet dissolution profiles of several commercial controlled-release proton pump inhibitors in simulated stomach and intestinal contents, as well as comparing name-brand and generic formulations of the same drug. In each case, vibrating tube sensor data revealed significantly different dissolution profiles for the different drugs, and in some cases our method also revealed differences between different pellets from the same drug product. By measuring any controlled-release pellets, particles, beads, or granules in any physiologically-relevant environment in a fully-automated fashion, this method can augment and potentially replace current dissolution tests and support product development and quality assurance in the pharmaceutical industry.
more »
« less
- PAR ID:
- 10285477
- Date Published:
- Journal Name:
- Scientific Reports
- Volume:
- 10
- Issue:
- 1
- ISSN:
- 2045-2322
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
null (Ed.)Abstract We present a method for creating a new type of model particle that allows us to measure the mass transfer rate from the particle surface to the surrounding water. We use hollow glass spheres and sugar to create neutrally buoyant particles in a variety of molded shapes. These particles are an alternative to traditional gypsum objects for measuring mass transfer, with the important characteristic of being neutrally buoyant. This is an inexpensive method that allows for custom particle shapes to be manufactured with different densities. We test the utility of these particles by measuring their dissolution rates in homogeneous, isotropic turbulence in our laboratory turbulence tank. Our measurements fit our proposed model, and give a faster dissolution rate for rod-shaped particles than for disc-shaped ones. Graphic abstractmore » « less
-
As pharmaceutical manufacturing is transitioning from traditional batch to continuous manufacturing (CM), there is a lack of tools for CM design and development, which can integrate drug substance and drug product unit operations for overall evaluation. Recently, a Python-based PharmaPy framework was proposed to advance the design, simulation, and analysis of continuous pharmaceutical processes. However, the initial library of models only addressed upstream drug substance processing. In this work, new capabilities, including drug product unit operations such as feeder, blender, and tablet press, have been added to the PharmaPy framework, enabling end-to-end study and optimizing the effects of material properties and process conditions on solid oral dosage products. The platform supports computational efficiency and model accuracy by allowing the development of different mechanistic and semi-mechanistic models. Sensitivity analysis is performed on the integrated end-to-end simulator to identify critical input variables influencing product quality and control strategies. The analysis lowers the complexity of the model by ranking significant input variables. Finally, feasibility studies are conducted on extracted influential input variables to characterize the process design space and achieve desirable output. The enhanced PharmaPy package can now support decision-making from early research and development stages through manufacturing.more » « less
-
Abstract Transdermal drug delivery is of vital importance for medical treatments. However, user adherence to long-term repetitive drug delivery poses a grand challenge. Furthermore, the dynamic and unpredictable disease progression demands a pharmaceutical treatment that can be actively controlled in real-time to ensure medical precision and personalization. Here, we report a spatiotemporal on-demand patch (SOP) that integrates drug-loaded microneedles with biocompatible metallic membranes to enable electrically triggered active control of drug release. Precise control of drug release to targeted locations (<1 mm2), rapid drug release response to electrical triggers (<30 s), and multi-modal operation involving both drug release and electrical stimulation highlight the novelty. Solution-based fabrication ensures high customizability and scalability to tailor the SOP for various pharmaceutical needs. The wireless-powered and digital-controlled SOP demonstrates great promise in achieving full automation of drug delivery, improving user adherence while ensuring medical precision. Based on these characteristics, we utilized SOPs in sleep studies. We revealed that programmed release of exogenous melatonin from SOPs improve sleep of mice, indicating potential values for basic research and clinical treatments.more » « less
-
This study presents a pioneering self-sustaining mechanism that exploits metabolic electron production from pre-loaded probiotics to power a vibrating capsule at a specific location in the gut. It is the first research to demonstrate the electrogenic properties of commercially available probiotics in a standard bacterial culture medium, Luria Broth (LB), and its application in generating vibration in a human stomach. The capsule is engineered with a miniature microbial fuel cell containing probiotics, an energy storage component (capacitor), a diode, and a vibrating motor. This assembly is enveloped in a Genipin-crosslinked mucoadhesive polymer to enhance adherence to the stomach lining and is further encapsulated within an acid-sensitive enteric coating to ensure selective dissolution in the stomach. This innovative approach heralds new possibilities for advanced gastrointestinal treatments by merging bio-electricity and biomechanics in a distinctive, patient-centric delivery system.more » « less
An official website of the United States government

